Thimble Point Acquisition Corp

Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The firm aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. It has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. The company’s lead product, reSET, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Its second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst for the treatment of chronic insomnia, was the first PDT submitted through the FDA's traditional 510(k) pathway while simultaneously reviewed through the FDA's Software Precertification Pilot Program. The company was founded on December 1, 2020 and is headquartered in Boston, MA.

The full company name is Sanswire Technologies Inc.

BOSTON--(BUSINESS WIRE)--Pear Therapeutics Announces the Inclusion of QuickMD in its Telehealth Provider Experience Initiative

Pear Therapeutics Announces the Inclusion of QuickMD in Its Telehealth Provider Experience Initiative

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Participate in the 17th Annual Needham Technology & Media Conference

Pear Therapeutics to Participate in the 17th Annual Needham Technology & Media Conference

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Participate in the Bank of America 2022 Healthcare Conference

Pear Therapeutics to Participate in the Bank of America 2022 Healthcare Conference

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Issue First Quarter 2022 Financial Results on Monday, May 16, 2022

Pear Therapeutics to Issue First Quarter 2022 Financial Results on Monday, May 16, 2022

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Present at 2022 Rx and Illicit Drug Summit

Pear Therapeutics to Present at 2022 Rx and Illicit Drug Summit

BOSTON--(BUSINESS WIRE)--Pear Therapeutics Receives Safer Technologies Program (STeP) Designation from FDA for Product Candidate to Treat Acute and Chronic Pain

Pear Therapeutics Receives Safer Technologies Program (STeP) Designation from FDA for Product Candidate to Treat Acute and Chronic Pain

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Participate in Upcoming Investor Conferences

Pear Therapeutics to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Pear Therapeutics Announces Program to Bring Prescription Digital Therapeutics to Patients in Recovery through a Telehealth Provider Experience

Pear Therapeutics Announces Program to Bring Prescription Digital Therapeutics to Patients in Recovery Through a Telehealth Provider Experience

Pear delivered well for the FY despite only being a post-revenue company for part of it.

Pear Therapeutics Guiding For Being 1% Down The Potential Runway In Current Markets

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Participate in Upcoming Investor Event Hosted by Credit Suisse

Pear Therapeutics to Participate in Upcoming Investor Event Hosted by Credit Suisse

Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q4 2021 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Pear Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Pear Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

BOSTON--(BUSINESS WIRE)--Pear Therapeutics Joins Epic App Orchard to Enable Clinicians to Monitor Prescription Digital Therapeutics

Pear Therapeutics Joins Epic App Orchard to Enable Clinicians to Monitor Prescription Digital Therapeutics

SoftBank Group Corp

Pear Therapeutics Inc (NASDAQ: PEAR) has agreed with SoftBank Group Corp (OTC: SFTBY) to develop a Japanese-language digital therapeutic for sleep/wake disorders for the Japanese market. In the U.S., Pear is marketing Somryst, the only FDA-authorized prescription digital.

Pear Therapeutics, SoftBank Team On Sleep/Wake Disorder Therapeutic For Japanese Market

BOSTON--(BUSINESS WIRE)--Pear Therapeutics Announces Agreement with SoftBank Corp. to Develop a Digital Therapeutic for Sleep/Wake Disorders for the Japanese Market

Pear Therapeutics Announces Agreement with SoftBank Corp. to Develop a Digital Therapeutic for Sleep/Wake Disorders for the Japanese Market

Pear Therapeutics Inc (NASDAQ: PEAR) announced data that further underscore the effectiveness of Somryst for chronic insomnia at the World Sleep 2022. Interim data from the DREAM study, analyzed in mid-Q1 2022, had 991 patients enrolled to date.

Pear Therapeutics' Digital Therapeutic For Insomnia Shows Meaningful Reductions In Severity Through 6 Months

BOSTON--(BUSINESS WIRE)--Pear Announces Data from Two Studies Evaluating Prescription Digital Therapeutics (PDTs) for Chronic Insomnia Presented at World Sleep Congress 2022

Pear Therapeutics Announces Data from Two Studies Evaluating Prescription Digital Therapeutics (PDTs) for Chronic Insomnia Presented at World Sleep Congress 2022

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Host Fourth Quarter and Full Year 2021 Earnings Conference Call and Webcast on March 28, 2022 at 4:30 p.m. Eastern Time

Pear Therapeutics to Host Fourth Quarter and Full Year 2021 Earnings Conference Call and Webcast on March 28, 2022 at 4:30 p.m. Eastern Time

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference

Pear Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference

BOSTON--(BUSINESS WIRE)--Pear Therapeutics Announces New CMS HCPCS Code for Prescription Digital Behavioral Therapy Inclusive of All of Its Commercial Products

Pear Therapeutics Announces New CMS HCPCS Code for Prescription Digital Behavioral Therapy Inclusive of All of Its Commercial Products

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Participate in Citi's 2022 Virtual Healthcare Conference

Pear Therapeutics to Participate in Citi's 2022 Virtual Healthcare Conference

BOSTON--(BUSINESS WIRE)--Pear Therapeutics Announces Availability of reSET® and reSET-O® in Spanish

Pear Therapeutics Announces Availability of reSET® and reSET-O® in Spanish

BOSTON--(BUSINESS WIRE)--Pear Therapeutics Announces State of Michigan to Fund Access to Prescription Digital Therapeutics for Substance Use and Opioid Use Disorders

Pear Therapeutics Announces State of Michigan to Fund Access to Prescription Digital Therapeutics for Substance Use and Opioid Use Disorders

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Participate in 9th Annual BTIG MedTech, Digital Health, Life Science & Diagnostics Conference

Pear Therapeutics to Participate in 9th Annual BTIG MedTech, Digital Health, Life Science & Diagnostics Conference

BOSTON & OKLAHOMA CITY--(BUSINESS WIRE)--Oklahoma Health Care Authority and Pear Therapeutics Enter into Value-Based Agreement for reSET® and reSET-O®

News for Thimble Point Acquisition Corp Stock (PEAR)